Polygenic risk scores for the diagnosis and management of dyslipidemia.

Liam R Brunham, Mark Trinder

Journal: Current opinion in endocrinology, diabetes, and obesity 2022;29(2):95-100

PMID: 35034034

Abstract

PURPOSE OF REVIEW

To review current progress in the use of polygenic risk scores for lipid traits and their use in the diagnosis and treatment of lipid disorders.

RECENT FINDINGS

Inherited lipid disorders, including those causing extremes of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides were initially identified as monogenic traits, in which a single rare variant with large effect size is responsible for the phenotype. More recently, a polygenic basis for many lipid traits has also been identified. Patients with polygenic dyslipidemia can be identified through the use of polygenic risk scores (PRSs), which collapse information from a handful to several million genetic variants into a single metric.

SUMMARY

PRSs for lipid traits may aid in the identification of the genetic basis for the lipid phenotype in individual patients, may provide additional information regarding the risk of cardiovascular disease, and could help in guiding therapeutic decision making.

Address: Centre for Heart Lung Innovation.; Department of Medicine.; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

DOI: 10.1097/MED.0000000000000708

Link outs

Free resources

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-BRIP1-5

Subscription / membership required

Full Text Sources:

MeSH Terms: Cholesterol, HDL, Dyslipidemias, Humans, Multifactorial Inheritance, Risk Factors, Triglycerides